(Q41841139)

English

Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies

scientific article published on 24 October 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 October 2017

Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies (English)

1 reference

Europe PubMed Central

13 October 2017

7

object named as

Karim Fizazi

1 reference

Europe PubMed Central

13 October 2017

Mary-Ellen Taplin

11

object named as

Mary-Ellen Taplin

1 reference

Europe PubMed Central

13 October 2017

9

object named as

Fred Saad

1 reference

Europe PubMed Central

13 October 2017

author name string

Joaquim Bellmunt

1

1 reference

Europe PubMed Central

13 October 2017

Thian Kheoh

2

1 reference

Europe PubMed Central

13 October 2017

Margaret K Yu

3

1 reference

Europe PubMed Central

13 October 2017

Matthew R Smith

4

1 reference

Europe PubMed Central

13 October 2017

Eric J Small

5

1 reference

Europe PubMed Central

13 October 2017

Peter F A Mulders

6

1 reference

Europe PubMed Central

13 October 2017

Dana E Rathkopf

8

1 reference

Europe PubMed Central

13 October 2017

Howard I Scher

10

1 reference

Europe PubMed Central

13 October 2017

Ian D Davis

12

1 reference

Europe PubMed Central

13 October 2017

Dirk Schrijvers

13

1 reference

Europe PubMed Central

13 October 2017

Andrew Protheroe

14

1 reference

Europe PubMed Central

13 October 2017

Arturo Molina

15

1 reference

Europe PubMed Central

13 October 2017

Peter De Porre

16

1 reference

Europe PubMed Central

13 October 2017

Thomas W Griffin

17

1 reference

Europe PubMed Central

13 October 2017

Johann S de Bono

18

1 reference

Europe PubMed Central

13 October 2017

Charles J Ryan

19

1 reference

Europe PubMed Central

13 October 2017

Stéphane Oudard

20

1 reference

Europe PubMed Central

13 October 2017

language of work or name

0 references

publication date

24 October 2015

1 reference

Europe PubMed Central

13 October 2017

European Urology

1 reference

Europe PubMed Central

13 October 2017

69

1 reference

Europe PubMed Central

13 October 2017

5

1 reference

Europe PubMed Central

13 October 2017

924-932

1 reference

Europe PubMed Central

13 October 2017

Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Castration-resistant prostate cancer: AUA guideline amendment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Enzalutamide in metastatic prostate cancer before chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Alpha emitter radium-223 and survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Castration-resistant prostate cancer: AUA Guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Abiraterone in metastatic prostate cancer without previous chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Progress in emerging therapies for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Secondary hormonal therapy for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

6 June 2018

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

18 August 2018

Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

18 August 2018

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

18 August 2018

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465643

18 August 2018

Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26508309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26508309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The "artificial" docetaxel space: the evolving treatment paradigm of metastatic castration-resistant prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26508309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Secondary Hormonal Therapy in Men With Castration-Resistant Prostate Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26508309

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.EURURO.2015.10.021

1 reference

Europe PubMed Central

13 October 2017

1 reference

Europe PubMed Central

13 October 2017

1 reference

Europe PubMed Central

13 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41841139&oldid=1663292063"